

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

14 - 20 September 2026



EU Moves to Restrict PET, Epoxy, and Glass Fiber Chemical Imports

The European Union is preparing safeguard measures to set import quotas on PET (Polyethylene Terephthalate) chips, epoxy resins, and glass fiber. Driven by rising trade imbalances, the quotas aim to curb surging Chinese exports, where European domestic PET prices over €825 (\$920) per tonne face lower Chinese FOB export prices of €700 (\$780). **(ChemNet Chemical Headlines)**

Global Sulfur Supply Shock Drives China CFR Prices to €959 Per Tonne

Global spot sulfur prices have surged past \$1,000 per tonne, driving Chinese CFR delivery costs to **€959** (\$1,065) per tonne. Shipping disruptions in the Strait of Hormuz and Russia's export ban through 2026 have severely tightened global supply, sharply inflating raw material costs for phosphate fertilizer production, pushing diammonium phosphate prices above \$820 per tonne. **(ChemNet Chemical Headlines)**

Surging Intermediate Costs Drive China Pigment and Dye Price Hikes

A surge in upstream intermediate costs triggered widespread price increases across China's pigment and dye sectors in September 2026. Leading producers issued consecutive price adjustment letters, with Reactive Brilliant Blue prices jumping by €12,780 (100,000 yuan) in two weeks to €38,360 (300,000 yuan) per tonne, placing severe cost pressure on downstream manufacturers. **(ChemNet Chemical Headlines)**

Twelfth Batch Centralized Drug Procurement Concludes With Dual-Anchor Mechanism

China has concluded the twelfth batch of centralized drug procurement with 327 enterprises and 521 products selected across 65 therapeutic categories including anti-infectives, antitumor agents, and antithrombotic drugs. This round introduces a dual-anchor mechanism to curb extreme low-price competition and guide the industry toward quality-oriented innovation rather than pure price wars. **(National Healthcare Security Administration)**

China Enforces Pharmaceutical Representative Management Measures

China enforced comprehensive measures for pharmaceutical representative management, establishing full oversight of academic promotion activities in the healthcare sector. The regulations prohibit representatives from undertaking sales quotas, collecting prescription data, or engaging in kickback schemes, while requiring a minimum educational background in medical or pharmaceutical disciplines. **(National Medical Products Administration)**